Jose Carlos L. MACHADO

Pubmed Publications List

Birthday: 14th July, 1969
Nationality: Portuguese
Address: 

Institute for Research and Innovation in Health – i3S

Rua Alfredo Allen 208

4200-135 Porto, Portugal

phone 351 225570796

E-mail josem@ipatimup.pt


Academic qualifications

  • 1992               Graduate degree in Biology by the Faculty of Sciences of the University of Porto.

  • 1994               M.Sc. degree in Oncobiology by the Faculty of Medicine of the University of Porto.

  • 1999               Ph.D. degree in Human Biology by the Faculty of Medicine of the University of Porto.

  • 2020               Habilitation in Biomedicine by the Faculty of Sciences of the University of Porto.

Postgraduate Training

1990 – 1991          Instructor in Zoology, Faculty of Sciences, University of Porto, Portugal.

1994 – 1997          PhD student, Institute of Anthropology and Human Genetics, University of Tübingen, Germany.

1997 – 1999          PhD student, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.

1999 – 2000          Postdoctoral Fellow, Department of Molecular Biology, University of Ghent-VIB, Belgium.

2000 – 2001          Postdoctoral Fellow, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.

Academic Appointments

2001 – 2007          Assistant Professor, Medical Faculty of Porto, Portugal.

2001 – 2014          Principal Investigador, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.

2007 – present     Associate Professor, Medical Faculty of Porto, Portugal.

2013 – present     Vice-President of the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP).

2015 – present     Principal Investigator at the Institute for Research and Innovation in Health (i3S).

2018 – present     Board of Directors member of the the Institute for Research and Innovation in Health (i3S).

2019 – present     Coordinator of the Cancer Programme at the Institute for Research and Innovation in Health (i3S).

Awards

1991 – 1992         Research Fellowship from Portuguese Scientific Research Board (JNICT).

1992 – 1994         M.Sc. Fellowship from Portuguese Scientific Research Board (JNICT).

1994 – 1999         Ph.D. Fellowship from Foundation for Science and Technology, Portuguese Ministry of Science and Technology.

1999 – 2001         Post-doctoral Fellowship from Foundation for Science and Technology, Portuguese Ministry of Science and Technology.

2000                      Young Researcher Prize from the European Cancer Prevention Organization (ECP).

2001                      Scholar-in-training Award for Promising Cancer Research from the American Association for Cancer Research (AACR).

2002                      Portuguese Society of Human Genetics Award

2004                      Portuguese Society of Gastroenterology Award

2005                      Portuguese Society of Gastroenterology Award

2018                      PFIZER 2018 Prize for Clinical Investigation.

Research Interest

The scientific question that drives my research is how mutations that arise in cancer cells spread among cell subpopulations and, in the process, help shape its plasticity and the tumor microenvironment. I want to understand how cancer cells communicate with each other and with other cells, and how does it influence, and is influenced, by clinical events such as therapy and disease progression. H. pylori-related gastric carcinoma is one of the central models of research we use.

Publications

10 Selected publications in the field of Cancer Research

1.         Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simões M. E-cadherin gene (CDH1) promoter                    methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20: 1525-1528, 2001.

2.         Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simões M.

            Interleukin1? and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121: 823-829,

            2001.

3.         Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-

            Simões M. Helicobacter pylori and interleukin-1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer

            Inst 94: 1680-1687, 2002.

4.         Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Alves CC, Campos ML, van Doorn LJ, Caldas C, Seruca R, Carneiro F,

            Sobrinho-Simões M. A pro-inflammatory genetic profile increases the risk of chronic atrophic gastritis and gastric carcinoma. Gastroenterology

            125: 364-371, 2003.

5.         Resende C, Regalo G, Durães C, Carneiro F, Machado JC. Genetic changes of CEBPA in cancer. Mutations or polymorphisms? J Clin Oncol 25:

            2493-2494, 2007.

6.         Canedo P, Corso G, Pereira F, Lunet N, Suriano G, Figueiredo C, Pedrazzani C, Moreira H, Barros H, Carneiro F, Seruca R, Roviello F, Machado JC.

            The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut

            57:1504-1508, 2008.

7.         Ferreira AC, Suriano G, Mendes N, Gomes B, Wen X, Carneiro F, Seruca R, Machado JC. E-cadherin impairment increases cell survival through

            Notch-dependent upregulation of Bcl-2 activation. Hum Mol Genet 21:334-343, 2012.

8.         Costa JL, Sousa S, Justino A, Kay T, Fernandes S, Cirnes L, Schmitt F, Machado JC. Non Optical Massive Parallel DNA Sequencing of BRCA1 and

            BRCA2 Genes in a Diagnostic Setting. Hum Mutat 34:629-35, 2013.

9.         Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P,

            Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus panel.

            Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66:6-30, 2017.

10.       Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C. Gastric microbial community profiling reveals a

            dysbiotic cancer-associated microbiota. Gut 2018 67:226-236, 2018.

Number of Publications

165

 

H index

41

10 best publications on Helicobacter

1.         Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simões M. Interleukin

            1? and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121: 823-829, 2001.

2.         Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-

            Simões M. Helicobacter pylori and interleukin-1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer

            Inst 94: 1680-1687, 2002.

3.         Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Alves CC, Campos ML, van Doorn LJ, Caldas C, Seruca R, Carneiro F,

            Sobrinho-Simões M. A pro-inflammatory genetic profile increases the risk of chronic atrophic gastritis and gastric carcinoma. Gastroenterology

           125: 364-371, 2003.

4.         Canedo P, Corso G, Pereira F, Lunet N, Suriano G, Figueiredo C, Pedrazzani C, Moreira H, Barros H, Carneiro F, Seruca R, Roviello F, Machado JC.

            The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut

            57:1504-1508, 2008.

5.         Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ,

            The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report.

            Gut 61:646-664, 2012.

6.         Ferreira RM, Machado JC, Letley D, Atherton JC, Pardo ML, Gonzalez CA, Carneiro F, Figueiredo C. A novel method for genotyping Helicobacter 

            pylori vacA intermediate region directly in gastric biopsy specimens. J Clin Microbiol 50:3983-3989, 2012.

7.         Correia M, Casal S, Vinagre J, Seruca R, Figueiredo C, Touati E, Machado JC. Helicobacter pylori’s cholesterol uptake impacts resistance to

            docosahexaenoic acid. Int J Med Microbiol 304:314-20, 2014.

8.         Resende C, Regalo G, Durães C, Pinto MT, Wen X, Figueiredo C, Carneiro F, Machado JC. Interleukin-1B signalling leads to increased survival of

            gastric carcinoma cells through a CREB-C/EBPβ-associated mechanism. Gastric Cancer 19:74-84, 2016.

9.         Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P,

            Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus panel.

            Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66:6-30, 2017.

10.       Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C. Gastric microbial community profiling reveals a

            dysbiotic cancer-associated microbiota. Gut 2018 67:226-236, 2018.

Editorial Boards

  • Member of the Editorial Board of the journal Helicobacter

  • Member of the Editorial Board of the journal Microbiota in Health and Disease

EHMSG Core Agency

WMA GmbH

Alser Strasse 4, 1090 Vienna, Austria

Contact

Tel.: +43 1 405 13 83 18

Fax: +43 1 405 13 83 918

© 2020

EHMSG c/o WMA GmbH

  • zwitschern

Follow us on Twitter

The EHMSG is a member of the United European Gastroenterology, a professional non-profit organisation combining all the leading European societies concerned with digestive disease.
UEG represents over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.